Observational, prospective study to examine the association between values of Bioelectrical impedance analysis (BIA) before and after treatment for cancer, clinical backgrounds, efficiencies of treatment, and adverse events

Observational, prospective study to examine the association between values of Bioelectrical impedance analysis (BIA) before and after treatment for cancer, clinical backgrounds, efficiencies of treatment, and adverse events - Observational, prospective study to examine the association between values of Bioelectrical impedance analysis (BIA) before and after treatment for cancer, clinical backgrounds, efficiencies of treatment, and adverse events

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037451

Enrollment

Registered

2019-07-29

Start date

2019-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patient who received ICI plus chemotherapyor platinum doublet alone as first-line regimen 2. Patient with recurrence lung cancer or unresectable progression caner 3.Diagnosis of small cell lung cancer or the non-small-cell lung cancer 4.Patient was 20 years oldor morehe at registration 5. Patient with Performance Status 0-2 5. Patient with the evaluable lesion 6. Written informed consent was obtained from the patient

Exclusion criteria

Exclusion criteria: Patient with a pacemaker

Design outcomes

Primary

Measure	Time frame
Association between ECW/TBW in BIA and efficiencies or adverse events of anti-cancer treatment	—

Countries

Japan

Contacts

Public ContactTomonori Hirashima

Ishikiriseiki Hospital Thoracic Oncology

t-hirashima@ishikiriseiki.or.jp0729883121

Outcome results